Cogstate Ltd · ASX:CGS
Cogstate — Shareholder Meeting (October 2009)
17 slides from Cogstate's shareholder meeting presentation, Oct 21, 2009
Slide 1: Annual General Meeting
For personal use only Annual General Meeting 21 October 2009 www.cogstate.com
Slide 2: Corporate overview & developments; FY2009 financial results
For personal use only Martyn Myer AO Chairman 1. Corporate overview & developments 2. FY2009 financial results www.cogstate.com
Slide 3: Our people are our strength
Our people are our strength • 32 FTE in Australia, USA and UK For personal use only • Scientific expertise – Dr Paul Maruff – Dr John Harrison – Dr David Darby – Dr Peter Snyder • Operational capabilities – Lead by Sophie Egholm (ex Pfizer, joined March 2009) – Staff in Melbourne, USA and UK • Techn
Slide 4: The importance of quality assurance
The importance of quality assurance • Regularly audited by customers for compliance with regulations as prescribed by regulatory authorities (eg FDA) For personal use only • Focussed on compliance with all applicable regulations • Full time QA manager based in Melbourne • Expect to have secured ISO9
Slide 5: Other important developments
Other important developments • Competitive marketplace – 3 key players in niche market (CGS, CDR, Cambridge Cognition) For personal use only – United BioSource Corporation (UBC) purchase of CDR after termination of UBC / CGS strategic partnership – UBC has sold 100% of their holding of CogState shar
Slide 6: The reasons for CogState's revenue growth
The reasons for CogState’s revenue growth • A structural migration towards computerised cognitive testing from the traditional paper and pencil methods; For personal use only • The pharmaceutical industry increasingly outsources non-core functions and now relies on specialist providers of niche serv
Slide 7: Profit driven by strong sales growth
For personal use only Profit driven by strong sales growth www.cogstate.com
Slide 8: Lower A$ helped boost sales revenue
For personal use only Lower A$ helped boost sales revenue www.cogstate.com
Slide 9: Larger clinical trials increase value of sales contracts
Larger clinical trials increase value of sales contracts For personal use only www.cogstate.com
Slide 10: Brad O'Connor, Chief Executive Officer
For personal use only Brad O’Connor Chief Executive Officer 1. Year to date trading conditions 2. Half year profit guidance www.cogstate.com
Slide 11: Strong trading conditions producing contract growth
Strong trading conditions producing contract growth • September quarter – revenue and cash receipts on target For personal use only – strong interest from new and existing customer base – US$3.18m (A$3.73m) contracts signed in Q1 www.cogstate.com
Slide 12: Contracted future revenue on the rise
Contracted future revenue on the rise • Contracted future revenue is secured by a signed sales contract and will be recognised as revenue upon achievement of a For personal use only milestone at a future point in time • 75% growth in contracted future revenue – 30-Sep-09: US$4.9m (or A$5.3m at US$0.
Slide 13: H1 revenue growth despite high A$
H1 revenue growth despite high A$ • H1 revenue forecast to be in range of US$4.0 – US$4.2m For personal use only • The prevailing exchange rates will impact on the amount of A$ revenue recognised Forecast US$4.0m - US$4.2m At US$0.92 exchange rate A$4.63m - A$4.75m At US$0.96 exchange rate A$4.52m -
Slide 14: US$ revenue growth on target
For personal use only US$ revenue growth on target www.cogstate.com
Slide 15: FY 2010: H1 Profit Guidance
FY 2010: H1 Profit Guidance Strengthening A$ will impact revenue and profitability For personal use only H1 Forecasts: Half Year (H1) Forecast US$0.92 US$0.96 $‘000,000 $’000,000 $’000,000 $’000,000 US$ revenue US$4.0 - US$4.2 US$4.0 - US$4.2 A$ revenue A$4.63 - A$4.75 A$4.52 - A$4.64 Operating Prof
Slide 16: Half Year Profit Comparison (at US$0.92)
Half Year Profit Comparison (at US$0.92) Half Year Results Jul 08 – Jan 09 – Jul 09 – Dec 08 Jun 09 Dec 09 For personal use only (Forecast) $’000,000 $’000,000 $’000,000 US$ revenue US$2.94 US$3.30 US$4.20 Average rate of conversion US$0.76 US$0.73 US$0.88 A$ Revenue A$3.87 A$4.52 A$4.75 Operating P
Slide 17: Brad O'Connor, Chief Executive Officer
For personal use only Brad O’Connor Chief Executive Officer CogState Ph: 03 9664 1300 boconnor@cogstate.com www.cogstate.com